Gland Pharma Limited — Important, 03-02-2025: Updates

**Financial Highlights:**

In Q3 FY25, Gland Pharma reported a revenue from operations of ₹13,841 million, reflecting a 10% decrease year-on-year and a 2% decline quarter-on-quarter. Total income was recorded at ₹14,426 million, down 9% YoY, while gross profit fell 3% YoY to ₹9,213 million, with a margin improvement to 67%. EBITDA of ₹3,600 million was slightly up, 1% YoY, and margins rose to 26%. Profit Before Tax (PBT) and Profit After Tax (PAT) saw increases of 6% and 7% respectively, with PAT at ₹2,047 million (15% margin).

**Strategic Initiatives and Growth Drivers:**

The company launched 13 new molecules during the quarter and continues to progress in the complex injectables segment, with nine filings and six products already launched. Furthermore, Gland aims to enhance its biologics CDMO collaborations to tap into growing demand.

**Business Developments:**

Gland Pharma has filed four ANDAs and received eight approvals during the quarter, contributing to a total of 366 ANDAs in the U.S. market, with 312 approved. The company also incurred a capex of ₹1,379 million during the quarter.

**Market Position and Competitive Advantage:**

Gland retains a strong position in the pharmaceutical market, aided by regulatory approvals and diversifying its product offerings, which is crucial for growth in a competitive landscape.

**Investor Implications:**

Investors should view Gland Pharma's recent performance cautiously, given the revenue decline yet encouraging growth in profitability and new product launches. The company's strategic focus on expanding its product portfolio and improving operational efficiency signals potential for future growth, warranting close attention as it navigates current market challenges.